New Triple-Action antibody takes on Hard-to-Treat cancers
NCT ID NCT07055594
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 28 times
Summary
This study tests a new drug called SOA101, a special antibody that targets cancer cells and helps the immune system attack them. It is for people with advanced solid tumors (like lung, ovarian, head and neck, breast, or colorectal cancer) who have no other good treatment options. The study will check the drug's safety, find the best dose, and see if it shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
China Medical University Hospital
RECRUITINGTaichung, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.